US 10717721

I'll search for authoritative information on this patent, including any 2026 CAFC docket activity.

Let me check for specific 2026 litigation/docket activity involving this patent.

Let me try to retrieve the granted claim language specifically.

US Patent 10,717,721 — Analyst Summary

Search scope note: I searched U.S. patent sources and litigation/docket aggregators. I found no 2026 CAFC docket entry specifically naming US 10,717,721. The Federal Circuit activity in the Helsinn/Akynzeo family I located concerns other patents (e.g., the earlier Helsinn v. Teva on-sale-bar appeals, and the 2026 PEROUTKA deposition transcript appearing in the PTAB IPRs), not the '721 patent itself. I flag that as a limitation below.

Bibliographic Data (from the patent front matter and Orange Book listings)

Family/continuity: A continuation-family member of the fosnetupitant series — sibling of US 8,426,450, US 8,895,586, US 9,403,772, US 9,908,907; parent of US 11,312,698 ("Fosnetupitant chloride hydrochloride having improved stability") and US 12,071,421 ("Process for the synthesis of substituted chloromethyl dialkylphosphates").

Commercial relevance: Listed in the Orange Book for AKYNZEO® (fosnetupitant chloride hydrochloride / palonosetron hydrochloride), NDA 210493, as a drug-substance patent with expiration 2032-05-23.

Abstract (paraphrased, per the patent)

Disclosed are compounds, compositions, and methods for the prevention and/or treatment of diseases pathophysiologically mediated by the neurokinin (NK₁) receptor. The compounds have the general formula (I), which covers substituted 4‑phenyl‑pyridine "piperazinium" derivatives — including the quaternized N‑(phosphonooxy)methyl prodrug fosnetupitant (designated GA1) and related N‑oxide and acyloxymethyl species.

Independent Claim Overview (plain language)

Caveat: The authoritative full patent text supplied to me includes the specification's enumerated embodiments but not the verbatim granted claim set. The overview below reflects the independent inventions the patent discloses and claims; I have not independently verified the exact wording/numbering of the granted independent claims.

1. Compound claim – genus. A compound of formula (I) (the substituted 4‑phenyl‑pyridine core with variable groups R, R¹–R⁶, X, Y, and Z), or a pharmaceutically acceptable salt or adduct thereof, subject to the proviso that if a non-pyridine N‑oxide (N⁻→O⁺) is present, the compound must contain more than one N‑oxide (an alternate embodiment expressly excludes all N‑oxide forms).

2. Compound claim – fosnetupitant (GA1). A compound of formula GA1: 4‑(5‑(2‑(3,5‑bis(trifluoromethyl)phenyl)‑N,2‑dimethylpropanamido)‑4‑(o‑tolyl)pyridin‑2‑yl)‑1‑methyl‑1‑((phosphonooxy)methyl)piperazin‑1‑ium, or a pharmaceutically acceptable salt/adduct thereof. (This is the netupitant phosphate-ester prodrug, i.e., fosnetupitant.)

3. Use / Swiss-type claim. Use of a therapeutically effective amount of a formula (I) compound (or salt/adduct) in the manufacture of a medicament for treating emesis, bladder dysfunction, depression, or anxiety.

4. Method-of-treatment claim. A method of treating emesis, bladder dysfunction, depression, or anxiety in a patient in need thereof by administering a therapeutically effective amount of a formula (I) compound (or salt/adduct).

5. Composition claim. A pharmaceutical composition comprising a therapeutically effective amount of a formula (I) compound (or salt/adduct) together with one or more pharmaceutically acceptable excipients, and (in dependent/embodied form) optionally a further therapeutic agent such as a 5‑HT₃ antagonist (e.g., palonosetron, ondansetron, granisetron, tropisetron), an NK₁ antagonist, or dexamethasone.

The disclosure also lists GA2–GA8 (1‑(acetoxymethyl)‑ and 1‑((butyryloxy)methyl)‑piperazinium species, and various mono-/di‑N‑oxides) and states a particularly preferred compound is the chloride hydrochloride (HCl) salt of GA1, said to be "tremendously resistant to decoupling of the oxo‑phosphonomethyl" — the basis for the stability-improvement patent US 11,312,698.

Litigation / Docket Context

• Helsinn Healthcare S.A. v. Gland Pharma (D.N.J., Nos. 3:22-cv-04635 and 2:22-cv-04635). Hatch‑Waxman §271(e)(2)/ANDA litigation over Akynzeo® IV. Gland's Paragraph IV notice (June 2, 2022) certified as to the '721 patent (among others), and Gland's Answer admits the '721 patent is Orange‑Book listed for NDA 210493.
• IPR2025‑00945 through ‑00949 (Azurity Pharmaceuticals v. Helsinn Healthcare). These 2025 IPRs target US 8,623,826; 9,186,357; 9,943,515; and 10,828,297 — not the '721 patent. I found no IPR naming the '721 patent.
• CAFC 2026: No 2026 Federal Circuit appeal specifically identifying US 10,717,721 was found.

Uncertainty Flags

• I could not retrieve a verbatim copy of the granted claims for this patent; the claim overview above is reconstructed from the patent's disclosed embodiments and should be verified against the official USPTO/Google Patents claim listing before reuse.
• Google Patents' legal-status and expiration entries are expressly labeled assumptions, not legal conclusions.
• I did not find any 2026 CAFC docket activity tied to patent number 10,717,721; if such an appeal exists, it was not surfaced by my searches, so absence of evidence here should not be read as confirmation that no appeal exists.

I'll search multiple litigation sources for US patent 10,717,721 specifically.

Let me dig deeper into the specific case and check for any additional litigation.

Let me verify whether any other cases (or appeals) name this patent specifically.

Known Litigation Involving US Patent 10,717,721

Bottom line

I found exactly one litigation naming US Patent 10,717,721 as an asserted patent:

Helsinn Healthcare S.A. v. Gland Pharma Limited — a Hatch-Waxman / ANDA action in the U.S. District Court for the District of New Jersey. It was resolved by a sealed consent judgment entered in late December 2022, with the case formally closed in January 2023 before any merits decision.

I found no other district-court action, no IPR/PGR, and no Federal Circuit appeal specifically identifying the '721 patent.

Case entry

Procedural timeline (key docket entries)

• June 2, 2022 — Gland's first Paragraph IV notice letter (certifying the '450, '586, '357, '772, '907, '073, '911, '721, and '297 patents).
• July 11, 2022 — Gland's second Paragraph IV notice letter (adding the '698 patent).
• July 18, 2022 — Helsinn complaint filed (Count VIII asserts the '721 patent).
• Oct. 2022 — Gland's counterclaims seeking declaratory judgments of non-infringement and invalidity of each patent, including the '721 patent (as part of the "First Notice Letter" group).
• Dec. 2, 2022 — Pretrial scheduling order entered (fact discovery to 2/24/2024; dispositive motions by 10/15/2024 — deadlines that were never reached).
• Dec. 22–23, 2022 — Consent Judgment and Dismissal Order entered under seal; matter marked closed.
• Jan. 18–19, 2023 — Public consent judgment / dismissal order entered; each party waived appeal rights.
• July 6, 2023 — Order granting Gland's motion to seal; the letter (Doc. 43) and consent judgment (Doc. 45) remain under seal.

Important nuances and flags

1. Case-number discrepancy (2:22-cv-04635 vs. 3:22-cv-04635). Google Patents' front-matter lists both "3:22-cv-04635" and "2:22-cv-04635" as separate Darts-ip/Unified Patents entries. Gland's own counterclaim pleading states Helsinn "filed a Complaint in Case No. 2:22-cv-04635," while the Consent Judgment and CourtListener docket use 3:22-cv-04635. These are the same action (the Newark/Trenton vicinage numbering changed); this is not two separate lawsuits. I flag it because the auto-populated litigation feeds present them as two rows.

2. "With prejudice" vs. "without prejudice" inconsistency in the dismissal language. The public order as signed by Judge Quraishi (Jan. 19, 2023) states: "all claims against Gland, or by Gland are dismissed with prejudice." The proposed/redacted consent-judgment text in the RECAP copy says the claims "are hereby dismissed without prejudice." A later sealing order (July 6, 2023) also states the letter and consent judgment "shall remain under seal." Per your strict rule, I'm reporting the discrepancy rather than resolving it; the entered (Jan. 19, 2023) order governs and reads with prejudice, but the differing proposed text should be verified against PACER if the precise dismissal type matters.

3. This is the same case already flagged in the prior section — that summary noted Gland's Paragraph IV certification and Answer admission but did not have the outcome. The outcome now supplied (sealed consent judgment → dismissal, case closed Jan. 2023) supplements, and does not contradict, the earlier section.

4. No other known litigation. My searches surfaced:

   • No IPR/PGR naming US 10,717,721 (the 2025 Azurity IPRs, IPR2025-00945 through -00949, target US 8,623,826; 9,186,357; 9,943,515; and 10,828,297 — not the '721 patent). This is consistent with the prior section.
   • No Federal Circuit appeal naming the '721 patent. (The Helsinn-related CAFC activity I found concerns other patents — e.g., the earlier Helsinn v. Teva on-sale-bar appeals — and the non-Helsinn CINVANTI/APONVIE appeals by Heron, which involve different patents entirely.)
   • The other Helsinn Akynzeo-related cases that appear in litigation feeds (Dr. Reddy's, Sandoz, Teva, Hospira, Actavis, Baxter, Mylan) concern earlier Helsinn patents (e.g., 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094) and do not name the '721 patent.

Sources

• Gland complaint Count VIII ('721 patent): https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.1.0.pdf
• Gland counterclaims (case no. 2:22-cv-04635, filing date, notice letters): https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.25.0.pdf
• Consent Judgment and Dismissal Order (public, dated Dec. 22, 2022 / entered 2023): https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf; CourtListener Doc. 50: https://www.courtlistener.com/docket/63601016/50/helsinn-healthcare-sa-v-gland-pharma-limited/
• Docket / motion-to-seal and closure entries: https://services.patexia.com/lawsuits/HELSINN-HEALTHCARE-SA-v-GLAND-PHARMA-LIMITED-id-165458/documents
• IPWatchdog Paragraph IV roundup (lists '721 among asserted patents): https://ipwatchdog.com/2022/07/29/patent-filings-roundup-future-waco-patent-cases-headed-wheel-ax-wireless-launches-wifi-6-campaign-helsinn-paragraph-iv-litigation/
• DrugPatentWatch case page: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=HELSINN+HEALTHCARE+S.A.+v.+GLAND+PHARMA+LIMITED|3:22-cv-04635
• Orange Book expiration listing ('721 = 2032-05-23, NDA 210493): https://thefdalawblog.com/wp-content/uploads/2021/01/obcs_2020_12.pdf; https://www.pharmakb.com/drug-report/fosnetupitant

Caveat: Searches were run against litigation aggregators (Unified Patents, Darts-ip, CourtListener/RECAP, DrugPatentWatch, Patexia) and PACER-derived sources. Absence of any additional case in these feeds is not affirmative proof that none exists — a very recent or foreign filing not yet indexed would not appear. Everything above should be confirmed against the live PACER docket for 3:22-cv-04635 (specifically the un-redacted entered dismissal order) if it is to be relied upon.

I'll verify against the canonical structured source and then check live sources for any recently-filed proceedings the ODP may not have indexed.

The searches confirm the Azurity IPRs hit sibling patents, not the '721. Let me run targeted confirmation checks.

Let me check for ex parte reexamination and any 2026 assertion activity.

Proceedings overview

There are zero AIA trial proceedings on file against US 10,717,721 — no IPR, no PGR, no CBM, at the PTAB. The canonical USPTO Open Data Portal structured block in this prompt returns no AIA trials for this patent, and my independent searches (Docket Alarm PTAB dockets, PTAB E2E/institution decisions, DrugPatentWatch's PTAB case table for the fosnetupitant/palonosetron product, and Google Patents' "family has litigation" flags) surfaced no petition ever naming the '721 patent. That is the entire answer to the count question: active = 0, invalidated = 0, sustained = 0, settled = 0, institution denied = 0.

Defensive posture bottom line: every claim of the '721 patent stands untouched and carries the statutory presumption of validity. There is no FWD to quote, no canceled claim to point at, and no § 315(e)(2) estoppel running against a future challenger on this patent. A defendant receiving a demand letter citing the '721 patent cannot say "the troll's claims are dead." It can say only that the PTAB route is still open — which for a compound/prodrug patent is a real but uphill option (see Strategic summary).

Critical framing caveat: the Azurity Pharmaceuticals IPRs that a casual search will surface in connection with Akynzeo® are filed against different patents. Do not conflate them with the '721. Details below.

Adjacent proceedings that do NOT involve the '721 patent (context only — no defensive value against the '721)

IPR2025-00945 / -00946 / -00947 / -00948 / -00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (five petitions)
• Filed: 2025-05-01 (all five)
• Patents challenged: US 8,623,826 ('826, IPR2025‑00945); US 9,186,357 ('357, IPR2025‑00946 and IPR2025‑00947 — two petitions, same patent); US 9,943,515 ('515, IPR2025‑00948); US 10,828,297 ('297, IPR2025‑00949). Source: institution decision text in IPR2025‑00948, which recites "The parties identify four petitions for inter partes reviews of related patents… IPR2025-00945 (regarding Patent 8,623,826 B2); IPR2025-00946 (regarding Patent 9,186,357 B2); IPR2025-00947 (regarding Patent 9,186,357 B2); IPR2025-00948 (regarding Patent 9,943,515 B2); and IPR2025-00949 (regarding Patent 10,828,297 B2)." The '721 patent is absent from that list.
• Status: Instituted. Institution decisions dated 2025-11-19 ("Request for Trial Granted," 2025-11-19, for US 8,623,826; 9,186,357; 9,943,515; and 10,828,297 — DrugPatentWatch legal-activity table for Akynzeo®).
• Judge panel (as named in the '948 institution decision): Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher J. Paulraj (Fitzpatrick writing). Panels for the companion cases may differ; I did not retrieve each panel roster, so treat '945/‑946/‑947/‑949 panel composition as unverified.
• Petition grounds: Obviousness under § 103 only (Helsinn's '297 Patent Owner Response states: "The Board instituted review of claims 1‑23 of U.S. Patent No. 10,828,297 … based on the Petition, which raises only obviousness grounds"). Azurity's core theory for the method patents: a POSA would have replaced aprepitant with netupitant (Bös) in the prior-art "triple therapy" regimen. Expert: Dr. Stephen J. Peroutka.
• Institution reasoning (one/two sentences): The Board found a reasonable likelihood of prevailing on at least one claim and instituted. Notably, PO filed discretionary-denial briefs (Paper 7 in '948; Paper 8 was Azurity's opposition), and "On September 19, 2025, then Acting Director Stewart denied discretionary denial and referred the Petition to the Board."
• Final Written Decision: None issued as of this analysis. With 2025‑11‑19 institution, the statutory 1‑year trial deadline puts FWDs around 2026‑11‑19 (subject to extension for good cause). The record shows the trial is in the merits phase — e.g., PO Exhibit 2086 is a 2026‑02‑25 deposition transcript of Azurity's expert referencing "IPR2025-00945, 946, 947, and 948 and 949."
• Settlement: None reported.
• Appeal: None — no FWD to appeal.
• Defensive value: Zero, for the '721. These proceedings concern the '826, '357, '515, and '297 patents (CINV method-of-treatment and combination/composition claims). Estoppel under § 315(e)(2) attaches petitioner-by-petitioner and patent-by-patent; it does not spill over onto the '721.

(Note: I saw a "PEROUTKA deposition" transcript in the search trail that the earlier summary flagged as 2026 activity in the PTAB IPRs — that is consistent with what I found (Exhibit 2086, 2026‑02‑25) and concerns the Azurity IPRs on the sibling patents, not the '721.)

District-court backdrop relevant to the PTAB posture

• Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. No. 2:22‑cv‑04635 (parallel No. 3:22‑cv‑04635). Filed 2022‑07‑18. The '721 patent was among the patents-in-suit. Gland's Paragraph IV notice (first letter, 2022‑06‑02) certified as to the '450, '586, '357, '772, '907, '073, '911, '721, and '297 patents; a second letter (2022‑07‑11) added the '698 patent. Gland's Answer confirms the Orange Book listings.
• The case terminated 2022‑12‑23 via Consent Judgment and Dismissal Order dated 2022‑12‑22. Gland did not file an IPR on the '721 (or, apparently, on any of the asserted patents) — so this litigation generated no PTAB framework and no § 315(a)/(b) events that constrain third parties.
• Source for the consent judgment: https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf
• Source for the Answer/counterclaims: https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf

No ex parte reexamination of the '721 was surfaced in my searches. I flag that as a negative finding rather than a certified absence — my searches hit a step limit before exhausting every reexam channel (USPTO Patent Public Search / reexam certificate listings).

Strategic summary

Canceled vs. sustained vs. untested. Because no AIA trial has ever been instituted against US 10,717,721, no claim is canceled and no claim is untested-because-invalidated — the correct characterization is "entirely untested at the PTAB and presumed valid." There is no narrowing to report and no list of surviving claims to give you; the patent stands exactly as granted on 2020‑07‑21. All claims, including the compound claim to GA1 (fosnetupitant) and the formula (I) genus, remain in force and enforceable. Anticipated expiration is 2032‑05‑23 (Google Patents; expressly an assumption). Note the front page carries a terminal disclaimer, so its term is tied to the earlier family member for § 154(b)/obviousness-type-double-patenting purposes — worth confirming against the parent's expiry if term matters to your analysis.

Estoppel landscape — this is the key point for a defendant. § 315(e)(2) estoppel is patent-specific and petitioner-specific. Azurity's IPRs on the '826/'357/'515/'297 patents generate no estoppel whatsoever against anyone on the '721. Practically, that means:

• A fresh petitioner can file an IPR on the '721 on any § 102/§ 103 ground it can muster, using patents and printed publications, with no "could have raised it before" bar.
• The only timing trap is § 315(b): you cannot file more than one year after you are served with a complaint alleging infringement of the '721. Gland was served in 2022, so Gland (and its privies/RPIs) is time-barred on the '721; a new defendant is not.
• PGR is unavailable — the nine-month post-grant window closed around 2021‑04‑21 for this patent. CBM is unavailable (not a covered business method / technological invention matter, and the CBM program is sunset).
• Ex parte reexamination remains available to anyone at any time, and given the 2026 environment (a ~190% Q1‑2026 spike in reexam filings and the Squires-era narrowing of IPR access, per RPX's Q1‑2026 in-review report), it is worth pricing as a fallback — with the caveat that ex parte reexam cannot use public-use or non-patent-publication prior art.

Pattern signals.

• No serial petitioner on the '721 — there is simply no petitioner at all.
• Helsinn is a vigorous, sophisticated PO but has not yet had to defend the '721 at the PTAB. In the neighboring Azurity IPRs it contested discretionary denial aggressively (separate briefs, with the Acting Director reportedly denying discretionary denial and referring the petition to the Board on 2025‑09‑19), signaling a PO that fights at the institution threshold and litigates the merits hard (its POPR/PO Response rely on hindsight-reconstruction and objective-indicia arguments).
• No defensive aggregator is in the chain. The known challenger is a commercial ANDA sponsor (Azurity/Slayback), not a Unified Patents-type entity. There is no systematic, multi-petitioner campaign against the '721.
• Note the asymmetry: Azurity attacked the method and combination patents but left the compound/prodrug patents ('772 fosnetupitant-as-compound, '907, '721, '698) alone. That is a deliberate choice — likely reflecting that the compound/prodrug claims are the harder target. Plan accordingly.

Recommended next steps

If you are a defendant and are being asserted on the '721:

• Do not rely on any PTAB cancellation — there is none. Any statement that "the '721 claims are invalidated" is false as of today. If an adversary asserts otherwise, the rebuttal is the PTAB docket itself: no proceeding number exists for US 10,717,721.
• Check your § 315(b) clock immediately — one year from the date you were served with a complaint alleging infringement of the '721. If you are inside the window, an IPR is available; if the complaint has been served and you're near the 12‑month mark, the window closes fast.
• Because no FWD exists, you cannot quote a disposition. The strongest available PTAB-based posture is a fresh IPR petition on the '721's own claims — and note the real-world friction: under the post‑March‑2025 bifurcated discretionary-denial framework and the Director's May 2026 precedential Magnolia Medical Technologies v. Kurin decision (IPR2026‑00097, 2026‑05‑14), a petition filed after adverse district-court developments faces a materially higher discretionary-denial risk. File early and cleanly, with RPI disclosure.
• Parallel-track ex parte reexam is worth evaluating, particularly in this 2026 environment where reexam volume is surging as IPR access tightens.

If active proceedings are pending — there are none against this patent, so there are no trial-stage milestones to track. The nearest live milestones are in the Azurity sibling IPRs: FWDs are due on/about 2026‑11‑19 (one year from the 2025‑11‑19 institution). If the Board cancels claims in the '826, '357, '515, or '297 patents, that narrows the Akynzeo® patent estate overall — but it does not touch the '721.

If you are a patent owner reading this: the absence of any IPR on the '721 after 5+ years and a full ANDA fight (the Gland litigation) is a genuinely favorable signal about the defensibility of the compound/prodrug claims. It also means your § 315(b) bar has already run against the one ANDA filer that was served — a useful shield against a repeat PTAB attack by that party or its privies.

Sources:

• Institution decision, IPR2025‑00948 (Azurity v. Helsinn, US 9,943,515), 2025‑11‑19: https://www.docketalarm.com/cases/PTAB/IPR2025-00948/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/
• IPR2025‑00945 PO discretionary-denial brief: https://www.docketalarm.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/
• Helsinn PO Response in IPR2025‑00949 ('297): https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents
• DrugPatentWatch PTAB case table for fosnetupitant/palonosetron (shows PTAB cases only for '297 and '357 — no '721): https://www.drugpatentwatch.com/p/alphasignals/litigation/drugname/index.php?query=fosnetupitant+chloride+hydrochloride%3B+palonosetron+hydrochloride
• DrugPatentWatch patent page for 10,717,721: https://www.drugpatentwatch.com/p/patent/10717721
• D.N.J. consent judgment (Helsinn v. Gland), 2022‑12‑22: https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf
• Magnolia Medical Technologies, Inc. v. Kurin, Inc., IPR2026‑00097 (PTAB 2026‑05‑14) (precedential): reported at https://www.vitallaw.com/news/patent-p-t-a-b-uspto-director-outlines-discretionary-policy-for-denying-iprs-denies-petition/ipm013455f9b9389b4f88915fd25a33eb27f5

Verification flags (do not skip):

1. No verbatim granted claim set for the '721 is in my hands (consistent with the earlier section). I have therefore described the patent's claim architecture generically and have not assigned claim numbers to any outcome — because there is no outcome to assign. Before citing "claim 1" or "claim 7" of the '721 in any brief, pull the granted claims from USPTO Patent Center / Google Patents.
2. The absence of an IPR is a negative finding. It rests on the ODP structured block (canonical) plus searches of PTAB dockets and drug-patent tables as of 2026‑09‑18. A petition filed very recently and not yet docketed could theoretically evade all of these sources. If institutional stakes are high, confirm directly in PTAB E2E by searching the patent number before relying on "no IPRs."
3. I was not able to complete a 2026 litigation sweep (search step limit) — so I cannot rule out that the '721 has been newly asserted in 2026 beyond the terminated Gland case. Excluding a new assertion matters for the § 315(b) clock.

I'll research the assignment record for US 10,717,721, starting with the USPTO Assignment Center and cross-referencing legal events.

Let me dig into the recorded reassignments and USPTO assignment records specifically.

Assignment & Ownership Analysis — US 10,717,721 B2

Source note (important): I attempted to query the USPTO Assignment Center (assignmentcenter.uspto.gov / assignment.uspto.gov) directly. It returned no assignment-record detail (no reel/frame, no correspondent, no execution dates) through the search interface available to me in this session. Everything below that is grounded is drawn from the Google Patents legal-events/assignments block for US 10,717,721, supplemented by the patent front matter, Orange Book listings, and litigation reporting. Where the Assignment Center would normally supply reel/frame and correspondent, I mark the field not retrieved rather than guess. This is a data-access limitation, not a finding that the records do not exist.

Inventors

Unusual pattern worth flagging (invention-provenance, not fire-sale): Inventor Valentino J. Stella is not a Helsinn scientist. He is the University of Kansas pharmaceutical chemist associated with the N-phosphoryloxymethyl prodrug platform, the very technology cited in this patent's own Background section (US 5,985,856, "to the University of Kansas"). His presence among seven Helsinn inventors signals an in-licensed academic platform folded into the netupitant core rather than a purely in-house invention. That is the opposite of a "departing-inventor" tell.

No evidence of inventor attrition within 12 months of filing (2018-12-21). The same inventor cohort (Fadini, Pietra, Giuliano, Lovati, Cannella, Venturini, +2) recurs across the sibling continuations (US 10,208,073; US 11,312,698), which is consistent with a stable, retained in-house R&D group, not a pre-sale exodus.

Original assignee

Helsinn Healthcare SA (Lugano/Pazzallo, Switzerland) — named on the issued patent as both original and current assignee.

• Line of business: Specialty pharmaceutical company; commercializes supportive-care oncology products.
• Did they ship a product embodying the claims? Yes — unambiguously. US 10,717,721 is listed in the Orange Book for AKYNZEO® IV (fosnetupitant chloride hydrochloride / palonosetron hydrochloride), NDA 210493, flagged DS (drug substance) in FDA's patent listing, with expiry 2032-05-23. The compound claimed in GA1 — 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium — is fosnetupitant, the active drug substance in the marketed IV product. Akynzeo (IV) was first approved 2018-04-19.
• Current status: Operating. No bankruptcy, dissolution, or fire-sale event appears anywhere in the record. It remains the current assignee after a 2023 release of a secured party's interest.

Assignment timeline

Google Patents' legal-events block shows only two recorded post-issuance conveyance entries, both of which are encumbrances (a security interest and its release), not ownership transfers. Reel/frame and correspondent were not retrieved — see source note.

• Executed date not retrieved / recorded 2022-12-30 — Reel not retrieved

  • Conveyance: Security Interest (SECURITY INTEREST — SEE DOCUMENT FOR DETAILS)
  • Assignor: HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC. (joint grantors)
  • Assignee: HAMILTON SA LLC
  • Correspondent: not retrieved. Because I could not obtain the recording document, I cannot confirm whether this correspondent recurs elsewhere in the chain — I decline to assert recurrence without the reel/frame. Flag: unverified.
  • Context: securitization — a lender/collateral agent taking a security interest over the Helsinn group's IP collateral (three affiliated Helsinn entities pledge jointly). This is financing collateral, not an acquisition.

• Executed date not retrieved / recorded 2023-09-20 — Reel not retrieved

  • Conveyance: Release by Secured Party (RELEASE BY SECURED PARTY — SEE DOCUMENT FOR DETAILS)
  • Assignor: HAMILTON SA LLC (releasing party)
  • Assignee (interest reverts to): HELSINN HEALTHCARE SA; HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN THERAPEUTICS (U.S.), INC.
  • Correspondent: not retrieved.
  • Context: termination of securitization — the lien is discharged and title/beneficial ownership reverts to the original Helsinn group with no intervening third-party owner.

Net ownership effect: the patent has never left the Helsinn corporate family according to the records surfaced. The chain is Helsinn → (lien to Hamilton SA LLC) → Helsinn. No assignment to any third-party acquirer, NPE, or aggregator appears.

Gap I must disclose: I could not retrieve the initial inventor→Helsinn assignment recording (typically filed near the 2011-11-29 priority filing or the 2018-12-21 continuation filing). Its absence from my results is a search-coverage gap, not a conclusion that it was never recorded. A verification pass against assignmentcenter.uspto.gov searching patent number 10717721 is required to capture that first link, plus the reel/frame/correspondent fields on the two entries above.

Timeline diagram

timeline
    title Ownership of US 10717721
    2011 : Priority filing by Helsinn
    2018 : Continuation filed by Helsinn
         : Application 16 228 835
    2020 : Patent issued to Helsinn
    2022 : Gland Pharma ANDA suit
         : Security interest to Hamilton SA LLC
    2023 : Lien released back to Helsinn

(Diagram reflects recorded/docketed events surfaced; the 2022-12-30 security-interest recording date is the recordation date, not a verified execution date.)

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. No transfer to any licensing-only LLC. The only non-Helsinn name in the chain, Hamilton SA LLC, took a security interest, not title, and released it within ~9 months. A collateral agent on a secured financing is the textbook absence of a shell-transfer signal.

2. Known asserter in the chain — Not present. Neither Helsinn Healthcare SA, Helsinn Birex Pharmaceuticals Limited, Helsinn Therapeutics (U.S.), Inc., nor Hamilton SA LLC appears on the Acacia / Marathon / IV / IPNav / Wi-LAN / Conversant / Vringo / Pendrell / MPHJ / Lumen View / Round Rock / Spangenberg catalogue, nor on the Unified Patents / RPX high-frequency-plaintiff directories I could reach.

3. Repeat correspondent across the chain — Unclear / not assessable. Correspondent is not retrieved for either recording. Per the task's own precision caveat, a single occurrence would not be a finding anyway; without the recording documents I cannot test recurrence. Suspend on this one.

4. Cascading transfers — Not present. Only two events, both within the same corporate family, and both security-related rather than transfers of title.

5. Pre-litigation transfer — Not present — and the chronology runs the wrong way for this signal. The Gland Pharma Paragraph IV/Hatch-Waxman suit (D.N.J. Nos. 3:22-cv-04635 and 2:22-cv-04635) was filed in 2022, with the Paragraph IV notice dated June 2, 2022; the security interest was recorded 2022-12-30, i.e., after suit began. There is no assignment to a litigation-vehicle entity in the six months before the suit. Helsinn is a plaintiff sui generis asserting its own marketed-product patent, not a transferee assembled for venue.

6. Bankruptcy fire-sale — Not present. No Chapter 7/11 or IP-asset auction involving Helsinn appears in the record.

7. Privateering — Not present. No transfer to an NPE to assert on Helsinn's behalf. Helsinn asserts directly, as an operating innovator, against ANDA filers.

8. Defensive aggregator (anti-NPE) — Not present. Chain does not terminate at RPX, AST, LOT, Unified, or OIN.

Verdict

Operating-company assertion.

US 10,717,721 has stayed inside the Helsinn corporate family throughout its recorded life: filed 2018-12-21 and issued 2020-07-21 to Helsinn Healthcare SA, momentarily encumbered by a security interest to Hamilton SA LLC (recorded 2022-12-30) and fully released back to Helsinn (recorded 2023-09-20). The current assignee ships a product embodying the claims — fosnetupitant chloride hydrochloride in AKYNZEO® IV, NDA 210493, where this patent is Orange-Book-listed as a drug-substance patent (expiry 2032-05-23) — and asserts it directly against an actual competitor (Gland Pharma) in the 2022 D.N.J. Hatch-Waxman actions. Zero NPE signals fire; the one unfamiliar name in the chain is a collateral agent on a financing, the functional opposite of an NPE transfer.

Verification link: https://assignmentcenter.uspto.gov/ (search patent number 10717721; also mirror at https://assignment.uspto.gov/patent/index.html). A manual pull there is needed to supply the reel/frame, execution dates, first inventor→Helsinn assignment, and correspondent that my search interface did not return.

I'll research the specific prior-art citations for US 10,717,721 directly from patent databases.

Let me gather the full prior-art citation list and details on key references.

US Patent 10,717,721 — Prior-Art Citation Analysis

Task note: I was asked to search the USPTO database for patent number 10717721 and analyze each of its cited references for §102 relevance. I retrieved the certified copy of the patent and the official "References Cited" list from the USPTO-derived mirrors (Google Patents patents.google.com/patent/US10717721B2; Justia patents.justia.com/patent/10717721; the USPTO-hosted PDF at patentimages.storage.googleapis.com). I did not query USPTO Patent Center's raw full-text API, so the citation list below is taken from the printed front-matter "(56) References Cited" of the '721 patent as reproduced by those mirrors.

Important scope caveat carried forward: the previously generated sections established that the authoritative full patent text supplied to me contains the specification's embodiments but not the verbatim granted claim set. The §102 mapping below therefore references claim categories (genus claim; GA1 claim; GA-compound claims; use/method/composition claims) rather than exact claim numbers, which I cannot verify from the material in hand. Where I cannot confirm that a reference discloses every element of a claim, I say so rather than force an anticipation finding.

1. The complete cited-reference list of US 10,717,721

The front matter lists the following. Dates are as printed/derived; descriptions marked "not independently verified" I could not confirm in this session.

1a. U.S. patent documents

1b. Foreign patent documents (as printed; identifiers reproduced literally)

• EP 1103545 — May 2001
• JP 2001-527083 — December 2001
• JP 2008-534454 — August 2008
• WO 2002/08232 — January 2002
• WO 2006/099968 — September 2006
• WO 2009/138393 — November 2009
• WO 2011/061622 — May 2011 (printed in the front matter as "20111061622")
• WO 2013/082102 — June 2013 (printed as "2013082102"; this is the family's own PCT publication of PCT/US2012/066778 — not prior art)

1c. Non-patent literature

• Kramer et al., Science 281(5383):1640-1645 (1998) — "Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors." ⚠️ Discrepancy flag: the body of the '721 specification, as supplied to me, renders this as "Kramer et al. (Science 281 (5383), 1640-1645, 1988)," while the front-matter "References Cited" list on Justia renders the author as "Kamer et al." and the year as 1998. Per the operating rule to interpret literally and not auto-correct, I report both renderings; the correct bibliographic year is 1998 (consistent with the '026 patent, which cites "Science, 1998, 281, 1640-1645").
• Gesztesi et al., Anesthesiology 93(4):931-937 (2000) — "Substance P (Neurokinin-1) Antagonist Prevents Postoperative Vomiting after Abdominal Hysterectomy Procedures."
• Hoffmann T. et al., Bioorg. Med. Chem. Lett. 16(5):1362-1365 (2006) — "Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists" (the paper that reports netupitant (21) and befetupitant (29)).
• Catalani et al., Bioorg. Med. Chem. Lett. 21(22):6899-6904 (2011) — "Identification of novel NK₁/NK₂ dual antagonists for the potential treatment of schizophrenia."
• Giuliani et al., Bioorg. Med. Chem. (2011) — "Non-peptide NK₁ receptor ligands based on the 4-phenylpyridine moiety."
• International Search Report, PCT/US2012/066778, dated 2013-01-03.
• Japanese Office Action dated 2015-08-25 (JP Appl. No. 2014-210716).

2. §102 anticipation analysis — the references that actually matter

Because the '721 patent's effective priority is 2011-11-29 (the family's filing is pre-AIA), a printed publication or patent that issued before 2011-11-29 is a §102(b) reference; a U.S. patent granted on an application filed before that date is a §102(e) reference. The three references below are the ones with genuine §102 exposure.

2.1 US 5,985,856 — Stella et al. (Univ. of Kansas), issued 1999-11-16

• Full citation: US 5,985,856 B1, "Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof"; filed 1998-12-30; priority 1997-12-31 (US 60/070,093); issued 1999-11-16.
• Description: Claims N-phosphoryloxymethyl prodrugs of tertiary/secondary amines of formula VIa/VIb, i.e., quaternary ammonium phosphate prodrugs in which R¹–R³ "comprise the parent tertiary amine" and the phosphate bears an organic/inorganic cation X and anion A. Worked examples are loxapine and cinnarizine prodrugs. This is the foundational Stella/Kansas "N-phosphonooxymethyl prodrug" disclosure. (Note the inventor overlap: Valentino J. Stella is a named inventor on both the '856 and the '721 — an inventor's-own-work citation.)
• §102 exposure: Not an anticipation of the GA1 claim. The '856 does not disclose the netupitant 4-phenyl-pyridine core, so it cannot disclose every element of the fosnetupitant claim. It is, however, the principal §102(b) reference against any generic claim to the N-phosphoryloxymethyl quaternary-ammonium (piperazinium) prodrug genus in its broadest form, and it is the strongest §103 combination partner with US 6,297,375.

2.2 US 6,297,375 — Bös et al. (Hoffmann-La Roche), issued 2001-10-02

• Full citation: US 6,297,375 B1, "4-phenyl-pyridine derivatives"; priority EP 99103504 (1999-02-24); issued 2001-10-02.
• Description: The genus patent for the 4-phenyl-pyridine NK₁ antagonists; it discloses netupitant — 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide — the parent tertiary amine of fosnetupitant. Also cited in the IPR2025-00947 petition as the "Bös" netupitant reference.
• §102 exposure: A §102(b)/§102(e) reference against any genus claim of formula (I) to the extent the claim reads on the un-quaternized parent (i.e., where Z is not the quaternary/phosphorylated embodiment), and against the use/method claims insofar as they recite netupitant as the active moiety. It does not anticipate the fosnetupitant (GA1) claim, because it contains no quaternized 1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium group.

2.3 US 6,747,026 — Hoffmann et al. (Hoffmann-La Roche), issued 2004-06-08

• Full citation: US 6,747,026 B2, "NK-1 receptor active amine oxide prodrugs"; priority EP 00115287 (2000-07-14); divisional of 09/904,059 (filed 2001-07-12); issued 2004-06-08.
• Description: Claims amine-oxide (N-oxide) prodrugs of 4-phenyl-pyridine NK₁ antagonists. Claim 1 covers the formula in which R⁴/R⁴′ form a cyclic tertiary amine; express claims include N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-oxy-morpholin-4-yl)-4-o-tolyl-nicotinamide and related N-oxides.
• §102 exposure: The single most relevant cited reference for the N-oxide claims of the '721 (GA4–GA8). The '721's independent claim carries the proviso that "if a non-pyridine N-Oxide (N⁻→O⁺) is present … the total number of N-Oxide on the compound … is more than one," and a separate embodiment "excludes all N-oxide forms." That proviso is the classic signature of an applicant carving the claim around a prior-art mono-N-oxide — and the '026 patent is exactly that prior art. So the '026 is a §102(b) reference against any mono-N-oxide claim and effectively forced the multi-oxide/exclusion proviso. Whether the '026 anticipates the specific netupitant-derived oxides GA4–GA8 depends on whether those exact 4-(o-tolyl)/2-(3,5-bis(trifluoromethyl)phenyl)propanamido structures fall within its disclosed genus; I could not confirm that in this session, so I flag it as likely overlapping but unverified.

3. §102 analysis — the remaining cited references (lower exposure)

Foreign documents: EP 1103545, JP 2001-527083, JP 2008-534454, WO 2002/08232, WO 2006/099968 and WO 2009/138393 are the PCT/foreign counterparts or background art of the Roche 4-phenyl-pyridine program and the amine-oxide prodrug program — relevant primarily as §102(a)/(b) family art to the same core disclosures as US 6,297,375 and US 6,747,026. WO 2013/082102 is the '721 family's own PCT publication (PCT/US2012/066778) and is not prior art. WO 2011/061622 (May 2011) postdates/abuts the priority date; I could not verify its subject matter or filing date in this session, so I cannot state whether it is §102 art — flagging this as unresolved.

Non-patent literature: Kramer (Kamer) et al. 1998 and Gesztesi et al. 2000 establish the utility of NK₁ antagonists for emesis/depression but disclose no compound structure relevant to the claims — background, no anticipation. The Hoffmann T. et al. 2006 BMCL paper is the most important NPL item: it expressly reports netupitant (compound 21) and its class-E pyridine series (with N-methylpiperazinyl and o-tolyl substituents), i.e., it is a §102(b) printed publication disclosing the parent drug (same exposure as US 6,297,375, but as a publication). The Catalani et al. 2011 and Giuliani et al. 2011 papers (4-phenylpyridine-based NK₁ ligands) are background to the chemotype. The ISR (PCT/US2012/066778) and the JP Office Action are prosecution documents, not prior art.

4. Bottom line

1. No cited reference anticipates the GA1 (fosnetupitant) claim. Neither US 5,985,856 (the phosphonooxymethyl-prodrug genus) nor US 6,297,375 (the netupitant genus) discloses the specific quaternized 1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium compound; only their combination would raise a §103 obviousness question, not §102.
2. The most §102-relevant reference is US 6,747,026 — the Roche amine-oxide prodrug patent — which almost certainly drove the '721's "more than one N-oxide" proviso and the alternative "excludes all N-oxide forms" embodiment, and is the closest art to the GA4–GA8 N-oxide claims.
3. US 6,297,375 (Bös) and the Hoffmann et al. 2006 BMCL paper are the primary §102 art against any claim reading on the netupitant parent; US 5,985,856 (Stella) is the primary §102(b) art against any generic claim to the phosphonooxymethyl quaternary-ammonium prodrug genus (and is the inventor's own prior work, given Stella's co-inventorship of the '721).
4. The three Helsinn/Fadini references and WO 2013/082102 are family-continuity citations, not prior art.

Verification flags

• I mapped references to claim categories, not verbatim claim numbers, because the granted claim set is not in my authoritative text (§unverified).
• Descriptions for US 6,303,790; 6,479,483; 6,531,597; 6,806,370 and 7,211,579 are marked not independently verified — I could not retrieve their disclosures in this session.
• The Kramer/Kamer and 1988/1998 discrepancy in the Science citation is reported, not resolved.
• The status of WO 2011/061622 as pre- or post-priority art is unresolved.
• I found no 2026 CAFC docket specific to US 10,717,721 (consistent with the earlier sections); the prior-art analysis above concerns the patent's own cited references only.

I'll ground this analysis in the prior art actually identified in the patent's own Background/Description of Related Art, then check for prosecution-history and third-party obviousness contentions.

Let me check for the '721-specific Paragraph IV invalidity contentions and the granted claim structure.

Let me verify the identity of two front-page WO references and the Krise non-patent art so I don't mischaracterize them.

Obviousness Analysis — US 10,717,721 B2 under 35 U.S.C. § 103

Scope note: This analysis builds on the prior Patent summary, Litigation, PTAB, and Assignment sections already generated; it does not repeat them. Consistent with the verification flags raised there, I still do not possess the verbatim granted claim set for the '721. I therefore analyze the two claim types the disclosure itself frames as inventions — the formula (I) genus and the formula GA1 species (plus the enumerated GA2–GA8 species and the chloride-hydrochloride salt) — and flag where the exact claim wording would change the analysis.

1. The prior art of record on this page

The patent's "Description of Related Art" and its front-page "References Cited" list supply the following. I treat the three expressly-discussed references as the core §103 art, and the balance as secondary/supporting art.

Excluded from the art (self/family): US 8,426,450, US 9,403,772, US 2017/0050993, and WO 2013/082102 are Fadini/Helsinn family members sharing the 2011-11-29 priority, so they are not §102/§103 prior art against the '721.

Literal-citation flag (do not auto-correct): The patent text on this page renders the Kramer reference as "Science 281 (5383), 1640-1645, 1988," whereas the companion Justia reference list renders it "Kamer et al. … Science 281(5383), 1640-1645 (1998)." I report both as found. Either way it predates the 2011 priority. Likewise, the patent body styles the '375 patent as "to Hoffmann-La Roche" while the front page names the inventor "Bos et al." — same document, different attribution convention.

2. Governing legal framework and the critical date

Critical date. The '721 carries a priority claim to 2011-11-29 and was filed 2018-12-21. The pre-grant publication (US 2019/0177296 A1) describes the application as a continuation-in-part of an earlier non-provisional, with a U.S. provisional 61/564,537. Practically:

• If the analyzed claims are supported by the 2011-11-29 disclosure, pre-AIA § 103 governs (AIA § 3(n)(1)) and the critical date is 2011-11-29.
• If a claim (e.g., a claim to the specific chloride-hydrochloride salt, or the FIG. 1 stability data) rests on new matter added later, AIA § 102/§ 103 governs and the effective date slides.

This distinction is outcome-neutral here, because every reference in the table above predates 2011-11-29 — the earliest possible date — by years. The obviousness case does not depend on winning the priority fight.

Test. Graham v. John Deere factors applied through KSR Int'l v. Teleflex: (1) scope/content of the art; (2) differences from the claims; (3) PHOSITA level; (4) secondary considerations. KSR permits combination where the art identifies a known problem with a finite number of identified, predictable solutions, and rejects the "rigid" TSM requirement — an "apparent reason" suffices.

3. Ground 1 — Bös '375 + Stella '856 (+ Krise) ⇒ GA1 and the formula (I) genus

3.1 Element-by-element mapping to GA1

GA1 = netupitant plus a quaternizing —CH₂—O—P(O)(OH)₂ on the N4-methylpiperazine nitrogen:

• 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl-1-methylpiperazin-1-ium, with —(CH₂)—O—P(O)(OH)₂ on N4.

The only element missing from Bös '375 is the phosphonooxymethyl group; the only element missing from Stella '856 is the netupitant core. That is the paradigm two-reference KSR combination.

3.2 Motivation to combine

1. Same recognized problem, same class of solution. The '026 patent (N-oxide prodrugs of the same 4-phenyl-pyridine NK1 antagonists) is in the record precisely because it sought to fix the parent compounds' aqueous insolubility for parenteral/bolus administration. The field thus understood both that netupitant-type compounds were too insoluble for IV use and that a bioreversible derivatization was the answer. Stella '856 supplied a second, independent, well-characterized derivatization for the identical problem.

2. Express teaching that the '856 chemistry is generalizable to tertiary amine drugs. The patent itself concedes the '856 patent is directed to "water soluble N-phosphoryloxymethyl derivatives of secondary and tertiary amines" — i.e., a class teaching, not a loxapine-only disclosure. Netupitant's reactive site (a 4-methylpiperazine tertiary amine) is the identical functional group found in loxapine, one of the '856 patent's two worked examples. A PHOSITA reading '856 would recognize a direct structural analogue.

3. The aprepitant/fosaprepitant lead. Fosaprepitant — the water-soluble phosphate prodrug of the NK1 antagonist aprepitant, marketed for IV use — was in the art and is the same class of drug (NK1 antagonist) solved by the same class of strategy (phosphate prodrug → enzymatic release of the parent). That is a specific, "same-problem/same-class" pointer that KSR treats as strong motivation, and it is far more than a "mere duplication of parts."

4. Finite, predictable solution set. Given a tertiary-amine NK1 antagonist that cannot be formulated for IV, the art offered (a) N-oxidation ('026), (b) N-phosphoryloxymethyl quaternization ('856/Krise), and (c) N-phosphoryl amidation (fosaprepitant). KSR is satisfied where the prior art gives a finite number of identified, predictable solutions and the applicant pursues one of them.

5. Reasonable expectation of success. Krise & Stella reported the N-phosphonooxymethyl prodrugs' in vivo conversion to parent in rats and dogs with good aqueous solubility. That is precisely the assurance a PHOSITA needs. The '721's own PK data (efficient conversion of compounds 1–3 to netupitant in rats and dogs; oral bioequivalence in dog) confirms the expectation was well founded — which cuts against, not for, nonobviousness.

3.3 Scope of formula (I) claim 1

Claim 1's genus is broader than GA1 and is met a fortiori: Bös '375 supplies the entire 4-phenyl-pyridine/NK1 sub-genus (X = —NR¹⁰¹C(O)—; Y = heterocycloalkyl); Stella '856 supplies the quaternized Z sub-genus recited in formula (I). A genus claim is obvious whenever the disclosed species are obvious, absent evidence of unpredictable criticality across the genus.

4. Ground 2 — Bös '375 + Hoffmann '026 ⇒ the N-oxide species (GA4–GA8)

This is the strongest single ground, and the '721's own claim drafting telegraphs it:

• '026 is directed to the exact compounds. "N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives" — the same 4-phenylpyridine NK1 scaffold, oxidized on the same substituent positions, expressly framed as prodrugs to improve aqueous solubility. Applied to netupitant (Bös '375), GA8 (netupitant piperazine 1-oxide) and its mono-/di-N-oxide congeners follow directly.
• The claim proviso is an admission-shaped footprint. Formula (I) as recited carries the proviso that "if a non-pyridine N-oxide (N⁻→O⁺) is present… then the total number of N-Oxide[s]… is more than one," and the disclosure elsewhere "excludes all N-oxide forms." Read against the art, that proviso is best understood as the applicant carving the '026 mono-N-oxide species out of the genus claim, which strongly suggests the mono-N-oxide species were recognized (rightly or wrongly) as too close to '026 to be claimed in the broad genus. A PHOSITA would reach the GA4–GA8 species by applying '026's N-oxidation prodrug teaching to Bös '375's netupitant.
• Counter to the "unexpected" defense. A propounded defense that the disubstituted/di-N-oxide selectivity was unpredictable must contend with the fact that the mono-oxide species — the ones '026 actually teaches — are the ones the applicant excluded.

Caveat: the '721's Background distinguishes '026 on the ground that "'026 reports no physicochemical or biological data." That is a §112/enablement-style criticism (does '026 enable?), not a §103 teaching-away argument, and it does not negate '026 as a §102/§103 disclosure. To the extent the applicant relies on it, expect the rebuttal that a reference need not disclose data to be prior art for §103.

5. Ground 3 — the acyloxymethyl species (GA2, GA3)

GA2 (1-(acetoxymethyl)-) and GA3 (1-((butyryloxy)methyl)-) are the ester analogues of the phosphonooxymethyl quaternization — i.e., the same N-alkylation of the piperazine nitrogen with a —CH₂—O—C(O)R leaving-group/handle. A PHOSITA starting from Bös '375 + Stella '856 would reach them as the immediate, obvious lower-ester homologues of GA1 by routine variation of the alkylating agent (chloromethyl acetate/butyrate in place of chloromethyl dialkyl phosphate). Acylozymethyl ("AM") quaternary ammonium prodrugs were a recognized prodrug motif, and In re Jones / In re Aller permit routine optimization of an identified class. Evidentiary caveat: this ground is weaker than Grounds 1–2 unless a reference specifically showing acetoxymethyl-quaternized tertiary-amine prodrugs is produced; I did not retrieve such a reference from the material on this page.

6. Ground 4 — the "chloride hydrochloride" salt of GA1

If (as the disclosure suggests) a claim is directed to the chloride hydrochloride of GA1, the obviousness case is materially weaker, for three reasons:

1. The reference point in the art taught the dibasic salt. The '721 states the "prior art preferred the use of dibasic salts of (phosphooxy)methyl substituents for quaternary ammonium salts in prodrugs," and that the inventors "found that such salts are unstable and reform the underlying drug during storage." Stella '856 independently claims cations such as "sodium, potassium, ammonium," i.e., the dibasic/alkali forms. So the art pointed away from the 2 HCl stoichiometry at issue.
2. The '721 presents this as the discovery. The disclosure states the chloride hydrochloride of GA1 "it has been found, is tremendously resistant to decoupling of the oxo-phosphonomethyl, and reversion of the active moiety to its parent state," supported by FIG. 1 (salt-dependent degradation over time; the disodium salt is the benchmark). That is an unexpected-results showing directed at exactly the salt-selection issue.
3. But note the overlap with the sibling patent. This stability work is the stated subject of US 11,312,698 ("Fosnetupitant chloride hydrochloride having improved stability"), which the earlier section flags as the continuation child of the '721. A challenger should determine which claims live in which patent before mounting a salt-form attack; a §103 attack on a salt claim in the '721 may be better aimed at the '698.

A generic "pharmaceutically acceptable salts are an obvious formulation choice" argument (Pfizer v. Apotex) is available but must overcome the specific, data-backed stability difference the specification reports.

7. Nonobviousness rebuttals the patent owner would (and does) press

These are the real battleground; a §103 conclusion that ignores them is incomplete.

8. Litigation-signal cross-check

The Gland Pharma counterclaims on record state grounds for the '297 patent (ALOXI Label; Bös; Dewan; EMEND Label) and the '698 patent (WO '846; Bös; Funk; DeGoey; Krise I; Oslob). I did not retrieve the Ground-by-Ground statement of invalidity for the '721 from the First Notice Letter, so I cannot represent what Gland actually asserted against it. Two observations:

• Krise I (Krise & Stella, N-phosphonooxymethyl prodrugs) appears in the '698 attack, which confirms that the '856/Krise art is being used in this very dispute — the same art that supports Ground 1 here. Expect it to be pressed against the '721 if it was not already.
• The '721's own "Prior art keywords" on the Google Patents page (alkyl, cycloalkyl, substituents, heterocycloalkyl, alkenyl) are auto-extracted tags, not references — do not cite them as prior art.

9. Bottom line

• GA1 (fosnetupitant) and formula (I) genus — prima facie obvious over Bös '375 + Stella '856, with Krise & Stella 1999 supplying the reasonable-expectation-of-success data and fosaprepitant supplying same-class motivation. This is a textbook KSR combination; the inability to muster it would be surprising.
• N-oxide species (GA4–GA8) — obvious over Bös '375 + Hoffmann '026, reinforced by the applicant's own proviso carving mono-N-oxides out of the genus claim.
• Acyloxymethyl species (GA2, GA3) — likely obvious as routine homologues; needs a supporting reference on acyloxymethyl quaternary-ammonium prodrugs.
• Chloride-hydrochloride salt of GA1 — the defensible frontier, resting on unexpected salt stability (FIG. 1) and on the art's preference for dibasic salts — and this territory substantially overlaps US 11,312,698.
• Net: the '721's commercial value (it is Orange-Book-listed as a DP (drug-product) patent, per the pharmakb listing, expiry 2032-05-23) does not track its obviousness exposure. The compound claims are vulnerable to a well-constructed two-reference case; the salt claims are not.

Verification flags

1. No verbatim claims retrieved. The claim-to-ground mapping above is keyed to the inventions the specification denominates (formula (I), GA1, GA2–GA8, chloride hydrochloride). Pull the granted claims from USPTO Patent Center / Google Patents before any filing, and confirm (a) which species are in which claim, (b) whether a salt claim exists in the '721 or only in the '698, and (c) whether any method-of-making claims were carried into the '721.
2. Effective filing date unverified. The '721's chain includes a continuation-in-part; whether a given claim is entitled to 2011-11-29 or a later date was not confirmed from the file history. The conclusion is date-robust, but the statute applied (pre-AIA vs AIA § 102/103) is not.
3. Kramer date discrepancy flagged literally (spec: "1988"; Justia list: "1998") — reported as found, not corrected.
4. '721-specific Paragraph IV grounds not retrieved. The Gland counterclaim grounds quoted are for the '297 and '698 patents. I did not confirm what §§ 102/103 art Gland asserted against the '721 in the First Notice Letter. If it matters, obtain the First Notice Letter and Gland's invalidity contentions from the (mostly closed/sealed) 3:22-cv-04635 docket.
5. '026's authorship/date: discussed in the '721 as "US 6,747,026 to Hoffmann-La Roche"; the corresponding EP 1303490 B1 (priority EP 00115287, 2000-07-14) is the same disclosure. Cite whichever the venue requires.